Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

Key Inclusion Criteria: Informed consent from parent(s) or other legally acceptable representative (LAR) to participate in the study Male or female, with a gestational age of ≥ 24 weeks and a post-natal age ranging from ≥ 3 days to ≤ 3 months Diagnosis of documented or presumed bacterial LOS requiring administration of systemic antibiotic treatment Sufficient vascular access to receive study drug and to allow blood sampling at a site separate from the study drug infusion line Key Exclusion Criteria: Refractory septic shock not responding to 60 minutes of vasopressor treatment within 48 hours before enrollment Proven ventilator-associated pneumonia Proven central nervous system infection (e.g., meningitis, brain abscess) Proven osteomyelitis, infective endocarditis, or necrotising enterocolitis Impaired renal function or known significant renal disease, as evidenced by an estimated glomerular filtration rate (using the Schwartz formula or other applicable formula) calculated to be less than 2/3 of normal for the applicable age group, OR urinary output < 0.5 mL/kg/h (measured over at least 8 hours), OR requirement for dialysis Progressively fatal underlying disease, or life expectancy < 30 days Use of systemic antibacterial therapy for longer than 48 hours within 7 days before start of study medication Participation in another clinical study with an investigational product within 30 days of enrollment in the current study